| abstract |
Disclosed herein are novel compounds Recognins termed Recognin M and Recognin L, belonging to a group of compounds termed Recognins, and produced, respectively, from artificial mammary and lymphoma cancer cells. Recognin M and Recognin L are useful for therapeutic and diagnostic purposes. They are each characterized by forming a single line precipitate with a specific antibody In quantitative precipitation tests and Ouchterlony gel diffusion tests; by being soluble in water and aqueous solutions having an acid or neutral pH, and Insoluble at an alkaline pH; having a spectrophotometric absorption peak wave-length of 280 mµ; and having a molecular weight of about 8,000 (as determined by thin layer gel chromatography). Recognin M contains approximately 90 and Recognin L approximately 92 aminoacid residues. |